Pericardial Histopathology and COVID-19 Seropositivity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study aims to investigate the association between pericardial histopathologic inflammation grades (acute, chronic, or absent) and COVID-19 seropositivity in adult patients undergoing first-time isolated coronary artery bypass grafting (CABG). Pericardial tissue samples were collected during surgery and evaluated histopathologically, while preoperative COVID-19 serological testing was performed. The primary outcome is to determine whether COVID-19 seropositivity is associated with the severity of pericardial inflammation. Patients with prior cardiac surgery, active COVID-19 infection, systemic inflammatory diseases, chronic immunosuppressive therapy, or malignancy were excluded from the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Response COVID-19 Pericardial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥20 years
* Undergoing first-time isolated coronary artery bypass grafting (CABG)
* Availability of pericardial tissue sample for histopathological analysis
* Preoperative COVID-19 serological testing performed
* Written informed consent obtained

Exclusion Criteria

* Previous history of cardiac surgery (e.g., prior CABG, valve surgery)
* Concomitant cardiac procedures during the same operation (e.g., valve repair, aortic surgery)
* Active COVID-19 infection at the time of surgery (positive PCR test)
* Known autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis)
* Chronic immunosuppressive therapy (e.g., steroids, biologics)
* Known malignancy at the time of surgery

Insufficient or inadequate pericardial tissue sample for histopathological assessment

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

emrah ereren

Role: STUDY_CHAIR

samsun university Faculty of medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samsun University Faculty of Medicine

Samsun, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

kvcsamsun

Identifier Type: -

Identifier Source: org_study_id